At this time, posts about Isu Abxis are rapidly increasing on portals and stock communities. Today, foreigners have net sold 28,000 shares of Isu Abxis, and institutions have net sold 5,000 shares, according to preliminary estimates. Isu Abxis is a subsidiary of the Isu Group, known for developing antibiotic treatments and providing medical services.
As of 1:30 PM on the 3rd, the stock price of Isu Abxis is 9,440 KRW, down 1.26% from the previous day, with a trading volume of 7,413,023 shares, which is 126.46% of the 5-day average trading volume. On February 23, Isu Abxis was a market topic due to the "agreement to produce the Russian COVID-19 vaccine," which caused an upward trend.
In addition to Isu Abxis, posts by investors are also surging for InterM (017250), KineMaster (139670), and Younghwa Metal (012280).
※Source: AI Investment Assistant AI Lassi
※ This article was generated in real-time by an automatic article generation algorithm jointly developed by Asia Economy and the financial AI specialist company Thinkpool.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
